MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

14 Jan 2022 Evaluate

Glenmark Pharmaceuticals has informed that it enclosed a media release on January 14,2021 titled ‘Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1783.25
Dr. Reddys Labs. 1202.40
Cipla 1329.50
Lupin 2007.10
Zydus Lifesciences 1154.00
View more..